Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GBIO

GBIO - Generation Bio Co Stock Price, Fair Value and News

$5.34 
Market Closed

44/100

GBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

44/100

GBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GBIO Price Action

Last 7 days

-4.5%

Last 30 days

-2.4%

Last 90 days

4.5%

Trailing 12 Months

-33.7%

GBIO RSI Chart

GBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GBIO Valuation

Market Cap

36.0M

Price/Earnings (Trailing)

-0.57

Price/Sales (Trailing)

2.36

Price/Free Cashflow

-0.31

GBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

GBIO Fundamentals

GBIO Revenue

Revenue (TTM)

15.3M

Rev. Growth (Yr)

-78.9%

Rev. Growth (Qtr)

108.37%

GBIO Earnings

Earnings (TTM)

-62.6M

Earnings Growth (Yr)

63.95%

Earnings Growth (Qtr)

73.62%

GBIO Profitability

Return on Equity

-123.87%

Return on Assets

-51.38%

Free Cashflow Yield

-318.88%

GBIO Investor Care

Shares Dilution (1Y)

0.88%

Diluted EPS (TTM)

-9.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202524.6M21.2M15.3M0
202410.0M13.2M18.6M19.9M
20230005.9M
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Generation Bio Co

GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://generationbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES150

Generation Bio Co Frequently Asked Questions

GBIO is the stock ticker symbol of Generation Bio Co. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Feb 10 2026, market cap of Generation Bio Co is 35.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Feb 10 2026, GBIO's PE ratio (Price to Earnings) is -0.57 and Price to Sales (PS) ratio is 2.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GBIO PE ratio will change depending on the future growth rate expectations of investors.